Hidekazu Suzuki

发表

Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002

J. Uchida, Y. Fukuda, S. Teramukai, 2022, Investigational New Drugs.

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).

K. Nagata, M. Kokubo, T. Yokoyama, 2021, Lung cancer.

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC

K. Kunimasa, F. Imamura, T. Morishima, 2022, Scientific Reports.

A Novel Model of Solitary Hepatic Tumor in Rats Using Ascites Hepatoma AH13: Suitability for Chemotherapeutic Studies

Y. Sakata, Yasuhide Yamada, S. Saitoh, 1990, Japanese journal of cancer research : Gann.

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.

H. Sumikawa, T. Kijima, M. Tamiya, 2022, European journal of cancer.

Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites

T. Wada, T. Morita, S. Inoue, 2021, BMC Cancer.

Antitumor effect of combination of murine recombinant interferon β, murine recombinant interferon γ and human recombinant interleukin-2 in MethA-bearing mice

Y. Sakata, S. Saitoh, Hidekazu Suzuki, 2005, Cancer Immunology, Immunotherapy.

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).

T. Yokoi, M. Tamiya, T. Sakagami, 2021, European journal of cancer.

Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study

Y. Matsuda, J. Uchida, M. Tamiya, 2023, European Journal of Clinical Pharmacology.

Histologic transformation of epidermal growth factor receptor-mutated lung cancer.

H. Akamatsu, S. Miura, T. Yokoyama, 2022, European journal of cancer.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer

Y. Yoshida, Y. Sakata, S. Saitoh, 2004, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study

Hidekazu Suzuki, A. Nishitani, M. Fujishima, 2018, BMC Cancer.

Drug-related pneumonitis induced by osimertinib as first-line treatment for EGFR-positive non-small cell lung cancer: a real-world setting.

H. Sumikawa, T. Yokoi, M. Tamiya, 2022, Chest.

Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer

S. Imoto, T. Aoshi, T. Irie, 2022, JCI insight.

The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2013, Chinese journal of cancer.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.

M. Okumura, A. Uzawa, F. O'Brien, 2019, Journal of the neurological sciences.

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).

T. Yokoyama, M. Tamiya, T. Sakagami, 2023, Lung cancer.